• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lixte Biotechnology Holdings, Inc. - Common Stock (NQ:LIXT)

3.370 -0.130 (-3.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,582
Open 3.420
Bid (Size) 3.110 (100)
Ask (Size) 3.460 (500)
Prev. Close 3.500
Today's Range 3.340 - 3.442
52wk Range 0.6400 - 6.260
Shares Outstanding 5,704,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment
April 24, 2026
Via Investor Brand Network
Topics Intellectual Property
MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape
April 17, 2026
Via Investor Brand Network
Topics Intellectual Property

Performance

YTD
-12.2%
-12.2%
1 Month
+10.5%
+10.5%
3 Month
-5.3%
-5.3%
6 Month
-23.9%
-23.9%
1 Year
+169.6%
+169.6%

More News

Read More
Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built
April 17, 2026
Via Investor Brand Network
Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients
April 15, 2026
Via Investor Brand Network
When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It
February 18, 2026
Via Investor Brand Network
BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference
April 13, 2026
Via Investor Brand Network
Topics Intellectual Property
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion
April 10, 2026
Via Investor Brand Network
Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships
April 09, 2026
Via Investor Brand Network
MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year
April 01, 2026
Via Investor Brand Network
Topics Intellectual Property
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
March 31, 2026
Via Investor Brand Network
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials
March 30, 2026
Via Investor Brand Network
Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership
March 26, 2026
Via Investor Brand Network
Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming
March 24, 2026
Via Investor Brand Network
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
March 20, 2026
Via Investor Brand Network
Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy
March 16, 2026
Via Investor Brand Network
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships
March 13, 2026
Via Investor Brand Network
Building a New Cancer Care Ecosystem: Liora’s Proton Therapy and LIXTE’s Drug Pipeline in Synergy
March 09, 2026
Via Investor Brand Network
TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline
March 06, 2026
Via Investor Brand Network
Topics Intellectual Property
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research
March 06, 2026
Via Investor Brand Network
Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy
March 02, 2026
Via Investor Brand Network
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care
February 23, 2026
Via Investor Brand Network
BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary
February 18, 2026
Via Investor Brand Network
Topics Intellectual Property
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement
February 13, 2026
Via Investor Brand Network
BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy
February 11, 2026
Via Investor Brand Network
Topics Intellectual Property
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment
February 09, 2026
Via Investor Brand Network

Frequently Asked Questions

Is Lixte Biotechnology Holdings, Inc. - Common Stock publicly traded?
Yes, Lixte Biotechnology Holdings, Inc. - Common Stock is publicly traded.
What exchange does Lixte Biotechnology Holdings, Inc. - Common Stock trade on?
Lixte Biotechnology Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lixte Biotechnology Holdings, Inc. - Common Stock?
The ticker symbol for Lixte Biotechnology Holdings, Inc. - Common Stock is LIXT on the Nasdaq Stock Market
What is the current price of Lixte Biotechnology Holdings, Inc. - Common Stock?
The current price of Lixte Biotechnology Holdings, Inc. - Common Stock is 3.370
When was Lixte Biotechnology Holdings, Inc. - Common Stock last traded?
The last trade of Lixte Biotechnology Holdings, Inc. - Common Stock was at 05/01/26 04:00 PM ET
What is the market capitalization of Lixte Biotechnology Holdings, Inc. - Common Stock?
The market capitalization of Lixte Biotechnology Holdings, Inc. - Common Stock is 19.22M
How many shares of Lixte Biotechnology Holdings, Inc. - Common Stock are outstanding?
Lixte Biotechnology Holdings, Inc. - Common Stock has 19M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap